60 Degrees Pharmaceuticals, Inc. (SXTPW) income statement

SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value

$0.03−0.00 (-0.38%)

Close on Oct 30, 2026Market cap $3.31MP/E –Yield –

60 Degrees Pharmaceuticals, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31
Revenue	0.21	0.16	0.30	0.44	0.10	0.16	0.24	0.14	0.12	0.11	0.13	0.05	0.06	0.02	–	0.17	0.05	–
Cost of Revenue	0.15	0.09	0.12	0.54	0.05	0.07	0.12	0.11	0.09	0.07	0.15	0.07	0.18	0.07	0.16	0.09	0.09	–
Gross Profit	0.06	0.08	0.18	-0.10	0.05	0.09	0.12	0.02	0.04	0.04	-0.02	-0.02	-0.12	-0.06	–	0.08	-0.04	–
Research & Development	0.60	0.28	0.64	0.81	0.23	0.37	0.61	0.94	3.10	0.34	0.10	0.26	0.20	0.12	0.20	0.03	0.23	–
General & Administrative	1.73	1.89	1.47	1.51	1.63	1.72	1.61	1.22	1.13	1.08	1.69	1.31	0.46	0.78	0.31	0.41	0.41	–
Operating Expenses	2.33	2.17	2.11	2.32	1.86	2.09	2.22	2.16	4.22	1.41	1.79	1.58	0.67	0.90	0.51	0.44	0.64	–
Operating Income	-2.27	-2.09	-1.92	-2.33	-1.61	-1.91	-2.07	-2.12	-4.19	-1.34	-1.89	-1.52	-0.79	-0.95	-0.68	-0.22	-0.69	–
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.22	0.00	1.10	1.14	1.11	1.22	0.91	–
Other Non-Operating Income	0.01	0.01	0.32	0.03	0.01	0.03	1.69	0.02	0.02	0.03	-0.01	-0.07	–	–	-0.01	0.00	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	-0.02	-0.12	0.00	–	0.08	-0.04	–
Pretax Income	-2.27	-2.09	-1.44	-2.32	-1.73	-1.88	-2.05	-2.16	-4.17	0.43	-2.05	4.17	-3.34	-2.60	-1.67	-1.45	-2.15	–
Income Tax Expense	–	–	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	0.04	0.08	-0.10	0.06	-0.12	-0.05	-0.17	0.23	-0.05	–
Net Income incl. Noncontrolling Interests	-2.27	-2.09	-1.44	-2.32	-1.73	-1.88	-2.05	-2.16	-4.17	0.43	-2.05	4.17	-3.34	-2.60	-1.67	-1.45	-2.15	-0.91
Minority Interest in Earnings	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.03	-0.01	-0.01	0.00	0.01	0.00	0.00	–
Net Income	-2.26	-2.09	-1.44	-2.32	-1.73	-1.88	-2.05	-2.16	-4.17	0.43	-2.01	4.18	-3.34	-2.60	-1.68	-1.45	-2.15	–
Preferred Dividends	0.13	1.33	0.13	0.13	0.13	0.82	0.13	0.12	0.12	0.34	–	–	–	–	–	–	–	–
Net Income to Common	-2.40	-2.21	-1.57	-2.44	-1.84	-2.00	-2.18	-2.27	-4.29	0.31	-2.08	4.09	-3.34	-2.60	-1.66	-1.45	–	–
EPS (Basic)(per share)	-0.90	-1.28	–	-2.64	-5.01	-6.25	–	-18.60	-84.48	7.32	–	182.60	-336.80	-271.20	-166.62	-146.40	-230.40	–
EPS (Diluted)(per share)	-0.90	-1.28	–	-2.64	-5.01	-6.25	–	-11.68	-84.48	7.32	–	182.60	-336.80	-271.20	-166.62	-146.40	-230.40	–
Shares Outstanding (Basic, Weighted)(shares)	2.65	1.73	1.07	0.92	0.37	0.32	–	0.12	0.05	0.04	0.02	0.02	0.01	0.01	0.01	0.01	0.01	–
Shares Outstanding (Diluted, Weighted)(shares)	2.65	1.73	1.07	0.92	0.37	0.32	–	0.54	0.05	0.04	0.02	0.02	0.01	0.01	0.01	0.01	0.01	–
EBITDA	-2.25	-2.08	-1.90	-2.31	-1.60	-1.90	-2.06	-2.11	-4.19	-1.34	–	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	–	–	–	–	0.01	1.76	-0.15	5.70	-2.56	-1.65	-0.99	-1.24	-1.46	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 19.4%
Operating margin: -774.9%
Net margin: -729.9%
Return on equity, FY2025: -196.4%

Financial strength

Current ratio: 2.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 63.7%

Valuation

P/E ratio: –
Price to sales: 2.98
Price to book: 1.26
Dividend yield: –